Dendrilife Cell-mediated Precise T-cell Immunotherapy
Cancer is among the worldwide leading causes of death, and poses a grave threat to people’s health and lives. Having the highest rate of tumor incidence, China possesses the highest number of cancer-related deaths worldwide. Statistics shows that, in 2015, there were 4.29 million cancer-related cases, among which the incidence of malignant tumors remained at a relatively high level. At the same time, cancer-related deaths reached 2.81 million. Therefore, in order to ease the situation, it’s important to develop more effective clinical treatment approaches.
Dendrilife cells (DCs) are the most powerful antigen pressing cells (APCs) that are in the immune system. With the MHC-I and MHC-II molecules on the surface of the cells, they allow antigen presentation to the T-cells and the activation of the immune functions. Yet, human blood contains an extremely limited number of DCs. Moreover, long-term cancer-fighting therapies will reduce the activity of DCs, in which case, they fail to comprehensively mediate an effective T-cell immune response. The self-developed DC-based precise immunotherapy can effectively solve this problem.
Different from the commonly used method that stimulates short-time DC proliferation with various cytokines, DC technology has achieved mass culture of DCs; the DC-based DCs can survive long-term in a culture without any activity reduction; meanwhile, DCs allow the engineering transformation to suit different cancers, representing an extensive anticancer spectrum. Furthermore, the DC technology is efficient in the activation of CTLs and NK cells, which enables both restrictive and non-restrictive immunotherapy, effectively preventing tumor immune escape and doubles the therapeutic efficacy. See the illustrations below:
DC Technology-based Treatment Process